BD, Quest Diagnostics colloborate forces to develop companion diagnostics for cancer, other diseases

BD (Becton, Dickinson and Company) and Quest Diagnostics have announced a global partnership to advance flow cytometry-based companion diagnostics (CDx) for cancer and other diseases. This collaboration will provide a comprehensive solution for CDx development, from exploratory panel creation to FDA-approved diagnostic kit production.

Companion diagnostics are crucial for selecting effective cancer treatments and optimizing patient outcomes. Current diagnostic technologies include immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), next-generation sequencing (NGS), and imaging. Flow cytometry, a well-established technique, will now be utilized to analyze and sort individual cells, offering insights into patients' immune responses and aiding in personalized treatment strategies.

Quest Diagnostics offers complete drug development services through its BioPharma services, including clinical trial testing and CDx development. BD is a global leader in medical technology, enhancing health through innovations in diagnostics and care.